At the news
? BULLISHIMPACT 8/10 8-K filed Feb 26, 2026 at 06:04 ET
BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and $5.3 billion, representing 33% and 40% year-over-year growth, respectively. Diluted GAAP earnings per ADS were $0.58 for Q4 and $2.53 for the full year. The company raised its full-year 2026 revenue guidance to $6.2-$6.4 billion, driven by BRUKINSA's global leadership and continued expansion.
- Total global revenues of $1.5 billion for Q4 2025, up 33% YoY
- Total global revenues of $5.3 billion for full year 2025, up 40% YoY
- Diluted GAAP EPS of $0.58 for Q4 2025 and $2.53 for full year 2025
- Full year 2026 revenue guidance of $6.2-$6.4 billion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access